Dissecting the cancer epigenome – fundamental lessons from developmental biology

This project aims to investigate the parallels between cancer epigenetics and early placental development to uncover novel regulatory mechanisms and their implications for disease.

Subsidie
€ 2.487.500
2024

Projectdetails

Introduction

DNA methylation is a tightly controlled mechanism that is essential for normal development and genome regulation. Although maintained in a highly static pattern across healthy tissues, DNA methylation is globally reprogrammed in nearly all malignant cancers, including gains at thousands of gene promoters and global loss across large domains.

Research Background

Substantial work from our group to characterize multiple primary tumor cohorts, transgenic animal models, and cancer cell lines finds that current experimental systems rarely, if ever, capture key features of the cancer epigenome.

Innovative Hypothesis

In contrast, our parallel efforts to understand epigenetic dynamics in development suggest an alternative, highly innovative hypothesis with a clear path for investigation. We find that the epigenetic alterations in cancer very closely mirror patterns that emerge in the early placenta, a tissue that naturally acquires invasive, immune suppressive, angiogenic, metabolically plastic, and mutationally tolerant properties.

Key Findings

Notably, this cancer-like epigenome depends on dynamic, previously undiscovered configurations of regulators that can be triggered without genetic mutation.

Methodology

With these insights, we have innovated tractable in vitro and in vivo platforms to dissect the biochemical, genetic, and physiological properties of this unique form of genome regulation as it supports developmental processes.

Future Directions

We believe these efforts will demonstrate that the placenta and, by extrapolation, the cancer epigenome reflect a switch-like reprogramming event that can be studied at high resolution.

Goals and Impact

In line with the ERC-ADG program’s goals, we will pursue ambitious and critical questions, resolve long-standing paradoxes, and provide a complete model of epigenetic transformation in development with direct disease implications.

Team and Resources

Our world-class interdisciplinary team, extensive preliminary data, experimental design, and proven track record will enable us to turn this grant into high-impact and translationally relevant discoveries.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.487.500
Totale projectbegroting€ 2.487.500

Tijdlijn

Startdatum1-1-2024
Einddatum31-12-2028
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EVpenvoerder

Land(en)

Germany

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Comprehensive Platform for the Functional Characterization of Cancer Epigenetics and Diagnosis

EpiCancer aims to develop single-cell epigenetic analysis tools to understand cancer heterogeneity and improve diagnostics through blood tests, enhancing early detection and monitoring of tumors.

€ 1.500.000
ERC Starting...

Detecting epigenetic biomarkers in the blood for non-invasive precision oncology

Develop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution.

€ 1.500.000
ERC Consolid...

Dynamics of Adaptation and Resistance in Cancer: MApping and conTrolling Transcriptional and Epigenetic Recurrence

This project aims to uncover the mechanisms of drug resistance in colorectal cancer through innovative models and computational methods, ultimately improving treatment strategies and patient outcomes.

€ 1.995.582
ERC Consolid...

Deciphering non-genetic determinants and targetability of cancer cell plasticity.

This project aims to reverse cancer cell plasticity in pediatric tumors using advanced genomic techniques to develop new therapeutic strategies for effective treatment.

€ 2.000.000
ERC Proof of...

Epigenetic profiling of menstrual blood for precision cancer detection and prevention

The EpiPrecise project aims to refine a cellular deconvolution algorithm for developing novel epigenetic tests to improve cancer detection and prevention strategies, particularly for women's cancers.

€ 150.000